Ken Griffin Ligand Pharmaceuticals Inc Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$82.7 - $110.11 $438,310 - $583,583	5,300 Added 441.67%	6,500 $651,000
Q2 2024 Aug 14, 2024	SELL	$68.53 - $87.91 $335,797 - $430,759	-4,900 Reduced 80.33%	1,200 $101,000
Q1 2024 May 15, 2024	SELL	$68.64 - $89.2 $123,552 - $160,560	-1,800 Reduced 22.78%	6,100 $445,000
Q4 2023 Feb 14, 2024	SELL	$49.57 - $72.63 $19,828 - $29,052	-400 Reduced 4.82%	7,900 $564,000
Q3 2023 Nov 14, 2023	SELL	$58.86 - $72.67 $41,202 - $50,869	-700 Reduced 7.78%	8,300 $497,000
Q2 2023 Aug 14, 2023	BUY	$69.53 - $79.33 $521,475 - $594,975	7,500 Added 500.0%	9,000 $648,000
Q1 2023 May 15, 2023	SELL	$65.67 - $77.08 $59,103 - $69,372	-900 Reduced 37.5%	1,500 $110,000
Q4 2022 Feb 14, 2023	SELL	$61.72 - $96.74 $129,612 - $203,154	-2,100 Reduced 46.67%	2,400 $160,000
Q3 2022 Nov 14, 2022	BUY	$0.01 - $107.56 $3 - $32,268	300 Added 7.14%	4,500 $388,000

256

18.1M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.91B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.